The Fierce Pharma website recently released a list of the top 10 pharmaceutical companies in terms of profits in 2021. The list shows that the new crown epidemic in 2021 has brought a sea change to the pharmaceutical industry, four of which derive their profits mainly from anti-new crown pneumonia drugs and vaccines, and two of which rely on the new crown vaccine to jump from zero to the top ten.

　　Novartis ranked di one with $24 billion

　　But the total revenue ranked fifth, profits mainly from the breakup with Roche to obtain a net profit of $ 14.6 billion, other profits of less than $ 10 billion, can barely enter the top ten.

　　Pfizer ranked di second with a profit of $21.98 billion

　　Total revenue was $81.29 billion. The new crown vaccine Comirnaty sold 36.78 billion, accounting for more than 40% of total revenue. 2022 Pfizer expects to sell 33 billion in vaccines while the antiviral drug Paxlovid is expected to reach $22 billion, potentially bringing full-year sales to more than $100 billion.

　　Johnson & Johnson ranked third with $20.88 billion

　　The company, the world's zui largest healthcare group, provided a lot of revenue from its consumer healthcare, and medical devices, respectively, in addition to $18.1 billion from its pharmaceutical business.

　　Roche ranked fourth with $15.24 billion

　　Its three anti-cancer drugs were challenged by various biologic anti-cancer drugs, and despite the launch of a new drug and a new crown pneumonia drug, revenues declined from the previous year.

　　Merck Sharp & Dohme ranked fifth with $12.35 billion

　　The main revenue came from two star products: the K-drug Keytruda and the HPV 9-valent vaccine Gardasil, with the former generating revenue of $30.98 billion.

　　Sixth and seventh place went to Moderna and BioNTech respectively

　　Sixth and seventh place were taken by Moderna with 12.2 billion and BioNTech with 12.16 billion dollars, while only -750 million and 15.6 million euros in 2020. They got the top 10 throne with only Spikevax and Comirnaty New Crown Vaccine, respectively.

　　Eighth place AbbVie has a profit of $11.55 billion.

　　The company is still eating the old money from Xumel, which is expected to bring in significant revenues until 2028, despite the imminent impact of generics on the drug.

　　Ninth place goes to Regeneron's $8.08 billion

　　Regeneron's monoclonal antibody REGEN-COV, which gained notoriety for curing former President Trump's new crown pneumonia, generated $6.2 billion in profits in 2021. 21 Regeneron's share price soared from $10.24 to $71.97, the highest increase zui of the ten companies.

　　The tenth place is Novo Nordisk's $7.59 billion

　　The products in the spotlight were the sugar-lowering weight-loss drugs Ozempic and Wegovy, which the company expects to reach $3.72 billion in weight-loss profits in 2025, double the previous estimate.
*** Translated with www.DeepL.com/Translator (free version) ***